Centauri TherapeuticsImmunotherapy company Centauri Therapeutics Ltd, based in Alderley Park, Cheshire, UK, has announced the appointment of Dr Debra Barker as Chief Medical Officer (CMO).
Tag Archive for: Novartis
lkov - adobe stock photoNovartis AG has reported a clinical milestone in the treatment of Sjögren’s syndrome, with its BAFF receptor blocker Ianalumab (VAY736) becoming the first investigational therapy to demonstrate a statistically significant reduction in disease activity in pivotal Phase III trials, as measured by the ESSDAI score.
adobe stock - peterschreiber.media Despite the World Trade Organisation’s (WTO) ban of tariffs on pharmaceuticals, US President Donald Trump has announced he would consider imposing tariffs on pharmaceutical products. In a fast reaction, Swiss pharmaceutical giants Roche and Novartis, which are heavily dependent on the US market, have announced upcoming investments in the US as a production location by 2030.
Johnson & JohnsonThe case of the psoriasis antiinflammation antibody guselkumab is a story of deals and cooperation and selling and buying royalties to fuel other innovation paths. J&J is right in the middle of the game and has now full ownership while expanding the indications further.
Roche, Herzog&De MeuronGenentech, the US arm of Swiss-based Roche AG, plans to acquire its long-time partner in allogeneic CAR-T blood cancer and gene therapies, Poseida Therapeutics Inc, for up to US$1.5bn.
© Niclas Jessen Studio/Bracco Imaging SpARadiopharmaceuticals specialist Blue Earth Therapeutics Ltd will use a U$76.5m Series A financing to finance Phase II development of its targeted prostate cancer radiopharmaceuticals Lutetium (177-Lu) rhPSMA-10.1 and Actinium (225-Ac) rhPSMA-10.1.